Semaglutide · research summary

SGLT2 inhibitors, semaglutide, and finerenone in diabetic kidney disease: a Bayesian network meta-analysis.

Frontiers in pharmacology · 2026. Summary drawn from the study's full text. Each statement is followed by the exact sentence it comes from. This is a research summary, not medical advice.

Study type

Bayesian network meta-analysis of phase 3 randomized controlled trials
“We conducted a Bayesian network meta-analysis comparing SGLT2 inhibitors, semaglutide, and finerenone—the three therapies with contemporary phase 3 cardiorenal evidence—to define their comparative efficacy and safety hierarchy in type 2 diabetes with chronic kidney disease.”

Subjects

Adults with type 2 diabetes and chronic kidney disease
“Population: Adults with type 2 diabetes and chronic kidney disease, defined by reduced eGFR and/or elevated UACR per individual trial thresholds.”

Sample size

20,521 participants
“Six trial-level datasets (CREDENCE, DAPA-CKD T2D subgroup, EMPA-KIDNEY T2D subgroup, FIDELIO-DKD, FIGARO-DKD, FLOW; N = 20,521) were included in the main analysis.”

Duration

Follow-up durations ranged from 2.0 to 3.4 years across included trials
“Follow-up durations ranged from 2.0 to 3.4 years, potentially differentially affecting the detection of late-occurring renal and cardiovascular events.”

Reported findings

SGLT2 inhibitors demonstrated the greatest risk reduction for kidney outcomes compared to semaglutide and finerenone
“Kidney outcomes: SGLT2 inhibitors demonstrated the greatest risk reduction (HR 0.70, 95% CrI 0.64–0.76; SUCRA 94.5%), followed by semaglutide (HR 0.76, 95% CrI 0.66–0.88; SUCRA 68.0%) and finerenone (HR 0.84, 95% CrI 0.77–0.92; SUCRA 37.5%).”
An indirect comparison showed a statistically significant kidney-protective advantage of SGLT2 inhibitors over finerenone
“The indirect comparison between SGLT2 inhibitors and finerenone reached statistical significance (HR 0.83, 95% CrI 0.73–0.95; posterior probability of SGLT2i superiority >99.9% [fixed effects]; 96% [random effects]).”
All three active agents significantly reduced cardiovascular risk versus placebo with no statistically significant differences between them
“All three active agents significantly reduced cardiovascular risk versus placebo, with no statistically significant differences between active agents.”

Limitations stated by the authors

The analysis relied on indirect comparisons due to a star-shaped network topology with no head-to-head trials, and the small number of trials per node
“The small number of trials per node (three for SGLT2 inhibitors, two for finerenone, one for semaglutide) is the foremost methodological limitation of this analysis.”

Source: PubMed 42851802 · DOI 10.3389/fphar.2026.1882227 · all study summaries

Study type

Bayesian network meta-analysis of phase 3 randomized controlled trials

“We conducted a Bayesian network meta-analysis comparing SGLT2 inhibitors, semaglutide, and finerenone—the three therapies with contemporary phase 3 cardiorenal evidence—to define their comparative efficacy and safety hierarchy in type 2 diabetes with chronic kidney disease.”

Reported findings

SGLT2 inhibitors demonstrated the greatest risk reduction for kidney outcomes compared to semaglutide and finerenone

“Kidney outcomes: SGLT2 inhibitors demonstrated the greatest risk reduction (HR 0.70, 95% CrI 0.64–0.76; SUCRA 94.5%), followed by semaglutide (HR 0.76, 95% CrI 0.66–0.88; SUCRA 68.0%) and finerenone (HR 0.84, 95% CrI 0.77–0.92; SUCRA 37.5%).”

An indirect comparison showed a statistically significant kidney-protective advantage of SGLT2 inhibitors over finerenone

“The indirect comparison between SGLT2 inhibitors and finerenone reached statistical significance (HR 0.83, 95% CrI 0.73–0.95; posterior probability of SGLT2i superiority >99.9% [fixed effects]; 96% [random effects]).”

All three active agents significantly reduced cardiovascular risk versus placebo with no statistically significant differences between them

“All three active agents significantly reduced cardiovascular risk versus placebo, with no statistically significant differences between active agents.”

Limitations stated by the authors

The analysis relied on indirect comparisons due to a star-shaped network topology with no head-to-head trials, and the small number of trials per node

“The small number of trials per node (three for SGLT2 inhibitors, two for finerenone, one for semaglutide) is the foremost methodological limitation of this analysis.”